552 related articles for article (PubMed ID: 30015968)
1. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
4. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
6. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
8. c-Met targeted therapy of cholangiocarcinoma.
Socoteanu MP; Mott F; Alpini G; Frankel AE
World J Gastroenterol; 2008 May; 14(19):2990-4. PubMed ID: 18494048
[TBL] [Abstract][Full Text] [Related]
9. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
[TBL] [Abstract][Full Text] [Related]
10. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells.
Srikoon P; Kariya R; Kudo E; Goto H; Vaeteewoottacharn K; Taura M; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2013; 14(7):4441-6. PubMed ID: 23992017
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
13. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
14. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
16. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
17. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
18. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
19. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
20. ALCAM is a Novel Cytoplasmic Membrane Protein in TNF-α Stimulated Invasive Cholangiocarcinoma Cells.
Adisakwattana P; Suwandittakul N; Petmitr S; Wongkham S; Sangvanich P; Reamtong O
Asian Pac J Cancer Prev; 2015; 16(9):3849-56. PubMed ID: 25987048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
